| Literature DB >> 16827938 |
Lars-Henrik Heckmann1, Richard Connon, Thomas H Hutchinson, Steve J Maund, Richard M Sibly, Amanda Callaghan.
Abstract
BACKGROUND: Transcriptomic techniques are now being applied in ecotoxicology and toxicology to measure the impact of stressors and develop understanding of mechanisms of toxicity. Microarray technology in particular offers the potential to measure thousands of gene responses simultaneously. However, it is important that microarrays responses should be validated, at least initially, using real-time quantitative polymerase chain reaction (QPCR). The accurate measurement of target gene expression requires normalisation to an invariant internal control e.g., total RNA or reference genes. Reference genes are preferable, as they control for variation inherent in the cDNA synthesis and PCR. However, reference gene expression can vary between tissues and experimental conditions, which makes it crucial to validate them prior to application.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16827938 PMCID: PMC1523214 DOI: 10.1186/1471-2164-7-175
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Candidate reference genes and target gene investigated
| Structural constituent of cytoskeleton (F) GO:0005200 | CCA CAC TGT CCC CAT TTA TGA A | CGC GAC CAG CCA AAT CC | 71 | ||||
| WFes0007807 | Microtubule (C) GO:0005874 | TGG AGG TGG TGA CGA CT | CCA AGT CGA CAA AGA CAG CA | 89 | |||
| WFes0012034 | Protein folding (P) GO:0006457 | GAC TTT CCA CCA GTG CCA TT | AAC TTT CCA TCG CAT CAT CC | 78 | |||
| Glycolysis (P) GO:0006096 | GGC AAG CTA GTT GTC AAT GG | TAT TCA GCT CCA GCA GTT CC | 89 | ||||
| WFes0009191 | Tricarboxylic acid cycle (P) GO:0006099 | TGC CAT TTA GTC GCA CTC AG | GTG AGC TTG TCC TCC TTT GC | 89 | |||
| WFes0002485 | Transcription initiation (P) GO:0006367 | GCA GGG AAG TTT AGT TTC TGG A | TGG TAT GCA CAG GAG CAA AG | 88 | |||
| WFes0003968 | Tryptophanyl-tRNA ligase activity (F) GO:0004830 | GCA CTG TGA TCA GCT CTT GC | TTT CGA TTG GAG GAA ATT CG | 82 | |||
| WFes0004602 | Ubiquitin-dependent protein catabolism (P) GO:0006511 | TCA CCT GCA CTC ACC ATT TC | AAT CTC CGG AAC CAA AGG AT | 90 | |||
| Protein biosynthesis (P) GO:0006412 | CGC TCT GAA TCA AGG GTG TT | TGT CCG ACC GTG AAG AGA GT | 77 | ||||
| Protein biosynthesis (P) GO:0006412 | GAG GCG CAA TGA AAG TGA AG | TGT TCG AGA CGG GAT CA | 70 | ||||
| Response to toxin (P) GO:0009636 | AAC CTA CAC CGA GGG TTT CG | TCC AAC ATT AAC GCC ATT AAG C | 70 |
aSeveral of the candidate reference genes are classified within multiple biological processes (P), molecular functions (F) or associated with one or more cellular components (C). A biological function, accompanied by a GO number, has been listed here for each gene (for more information visit ).
bTarget gene also known as 15-oxoprostaglandin 13-reductase or more generally as NADP(H)-dependent alkenal/one oxidoreductase
Relative gene expression and variability of candidate reference genes
| 1.000 ± 0.078 | 0.963 ± 0.035 | 1.030 ± 0.044 | 1.001 ± 0.040 | 0.119 | 0.795 ± 0.066 | |
| 1.000 ± 0.129 | 0.896 ± 0.126 | 0.885 ± 0.095 | - | 1.010 ± 0.016 | ||
| 1.000 ± 0.040 | 0.949 ± 0.103 | 0.900 ± 0.015 | - | 1.038 ± 0.016 | ||
| 1.000 ± 0.093 | 0.914 ± 0.059 | 0.919 ± 0.047 | 0.879 ± 0.067 | 0.098 | 0.946 ± 0.029 | |
| 1.000 ± 0.145 | 0.889 ± 0.170 | 0.950 ± 0.180 | 1.027 ± 0.026 | 0.160 | 0.992 ± 0.015 | |
| 1.000 ± 0.096 | 0.786 ± 0.176 | 0.788 ± 0.153 | 1.038 ± 0.084 | 0.192 | 0.925 ± 0.016 | |
| 1.000 ± 0.117 | 0.954 ± 0.098 | 0.906 ± 0.060 | 0.955 ± 0.081 | 0.136 | 0.922 ± 0.064 | |
| 1.000 ± 0.040 | 0.995 ± 0.095 | 1.024 ± 0.016 | 0.888 ± 0.097 | 0.098 | 1.034 ± 0.013 | |
| 1.000 ± 0.279 | 2.096 ± 1.074 | 2.506 ± 1.640 | 2.204 ± 0.910 | 0.430 | 0.853 ± 0.089 | |
| 1.000 ± 0.261 | 1.247 ± 0.445 | 1.410 ± 0.560 | 1.457 ± 0.616 | 0.313 | 0.846 ± 0.020 | |
Gene name abbreviations as Table 1.
aValues are mean ± SD (IB refers to ibuprofen). Expression levels are displayed relative to the mean control level.
bGene variability is estimated by geNorm as the variation (SD) of a given reference gene relative to the remaining reference genes (Atb and Cyp are not included in the analysis as they are significantly down-regulated by IB).
cHighest treatment (80 mg IB l-1) significantly different from any other treatment (p < 0.05).
dHighest treatment (80 mg IB l-1) significantly different from control (p < 0.05).
Figure 1Pairwise variation of sequential normalisation factors (. NF2 is based on the geometric mean of GAPDH and UBC; NF3 is NF2 and Act; NF4 is NF3 and WARS; NF5 is NF4 and SDH; NF6 is NF5 and TBP; NF7 is NF6 and 28S; NF8 is NF7 and 18S (gene name abbreviations as Table 1).
Figure 2Relative gene expression of target gene . Mean relative expression (n = 3) ± SD of target gene Ltb4dh (amplification efficiency E = 1.060 ± 0.042) without normalisation (white bars) or with normalisation (black bars) to normalisation factor NF3 based on the geometric mean of Act, GAPDH and UBC (gene name abbreviations as Table 1). Expression levels are displayed relative to the mean control level. An asterisk (*) indicates a significant difference (p < 0.05) between the highest treatment and any other treatment.
Figure 3Relative gene expression of target gene . Mean relative expression (n = 3) ± SD of Ltb4dh following normalisation to 10 candidate reference genes and a normalisation factor (NF). Expression levels are displayed relative to the mean control level. For comparison, the normalised relative expression of Ltb4dh is displayed by treatment group. Relative expression of Ltb4dh normalised to: Act (1); Atb (2); Cyp (3); GAPDH (4); SDH (5); TBP (6); WARS (7); UBC (8); 18S (9); 28S (10); NF3 based on the geometric mean of Act, GAPDH and UBC (11); and Ltb4dh without normalisation (12) (gene name abbreviations as Table 1). An asterisk (*) indicates a significant difference (p < 0.05) from Ltb4dh normalised by NF3.